The wave of AI applications in healthcare is hotter than ever.

A new study from NVIDIA shows that artificial intelligence is rapidly becoming a key transformative driver in healthcare and life sciences. According to a study titled 'State of AI in Healthcare and Life Sciences', approximately 70% of organizations in the industry have deployed AI, a significant increase from 63% the previous year.

 

This survey, based on feedback from over 600 industry professionals, shows that the healthcare sector has moved beyond the initial testing phase. Instead of just deploying pilot projects, many organizations are putting AI into practical operation with measurable return on investment (ROI).

AI-generated content is booming in the healthcare industry.

The most significant growth has come from generative AI and large language models (LLM). Currently, about 69% of healthcare organizations are using these technologies, up from 54% the previous year.

Within the sub-sectors, the digital healthcare sector leads with an adoption rate of 78%. The pharmaceutical and biotechnology sectors rank second with 74%, while medical device technology reaches 70%.

Even segments that traditionally adopted technology more slowly are catching up. Insurance companies and healthcare providers have increased their AI adoption rates from 43% to 56% in just one year.

AI is also being integrated more deeply into clinical practices. According to the report, 42% of organizations use AI to support clinical decision-making, while 38% apply AI for medical image analysis and a similar percentage use AI to optimize administrative processes.

According to John Nosta, president of the medical research organization NostaLab, the most noticeable impact of AI in the early stages will come from improvements in operational efficiency.

 

He argued that the most visible and scalable benefits of AI lie in optimizing logistics and simplifying administrative processes in the healthcare industry.

Targeted AI applications yield clear returns.

The report indicates that AI delivers the highest financial returns when applied to specific and clearly defined problems.

In the medical device technology sector, 57% of businesses reported achieving ROI from AI in medical image analysis. Similarly, 46% of pharmaceutical and biotechnology companies reported profits from using AI in drug discovery and development.

Annabelle Painter, head of clinical AI strategy at Visiba, emphasizes that expanding AI in healthcare should begin with real-world clinical and operational problems, rather than focusing solely on technology.

From a business efficiency perspective, the survey shows that 85% of leaders reported that AI helped increase annual revenue, while 80% said operating costs had decreased.

Notably, 44% of businesses reported revenue increases of more than 10% thanks to AI. Smaller companies benefited particularly, with 56% reporting revenue increases of over 10%.

This shows that by focusing on applications with significant impact and clear measurable metrics, businesses can quickly demonstrate the value of AI and lay the foundation for future expansion of the technology.

 

Artificial AI – the next wave of AI in healthcare

Another prominent trend is the emergence of agentic AI, which refers to AI systems capable of reasoning independently and performing tasks automatically.

According to NVIDIA data, 47% of organizations are using or evaluating AI agents, with 22% having already implemented them.

The most common applications of agentic AI include knowledge management and retrieval (46%), research document analysis (38%), and internal process optimization (37%).

In the pharmaceutical and biotechnology industries alone, 55% of organizations use AI agents to analyze scientific literature, and nearly half deploy this technology in new drug research.

Open-source tools also play a crucial role in the scaling of AI. Approximately 82% of organizations indicated that open-source models and software are critical to their AI strategy, as they allow for model customization for specialized research and clinical tasks.

Positive financial results are driving businesses to continue increasing investment in AI. According to the report, 85% of organizations expect to increase their AI budgets, and nearly half predict the increase will exceed 10%.

New investments are primarily focused on expanding and optimizing proven AI solutions, with 47% of businesses indicating they would prioritize improving AI-based workflows.

However, the implementation process still faces some challenges. Smaller organizations often struggle with budget constraints, with 40% citing cost as the biggest barrier. Around 33% also reported a lack of sufficient quality data to train their AI models.

Meanwhile, large businesses are more concerned about privacy and data security, with 39% considering it a major issue.

Data shows that AI in healthcare and life sciences has moved beyond its initial testing phase. With high adoption rates, increasing revenue, and growing investment budgets, AI is gradually being deeply integrated into clinical processes, drug research, and healthcare operational systems.

This shows that AI is no longer just a technological trend, but is becoming a core part of the future of global healthcare.